Emerging targeted therapies in meningiomas.

IF 4.4 2区医学 Q1 CLINICAL NEUROLOGY

Current Opinion in Neurology Pub Date : 2025-10-09 DOI:10.1097/WCO.0000000000001430

Erika Yamazawa, Emily Sullivan, Hiroaki Wakimoto, Priscilla K Brastianos

{"title":"Emerging targeted therapies in meningiomas.","authors":"Erika Yamazawa, Emily Sullivan, Hiroaki Wakimoto, Priscilla K Brastianos","doi":"10.1097/WCO.0000000000001430","DOIUrl":null,"url":null,"abstract":"Purpose of review: Patients with grade 2 and 3 meningioma have high recurrence rates and limited treatment options after failure of radiation and surgery. Recent advances in molecular profiling of these tumors have enabled the investigation of novel targeted therapeutic approaches.Recent findings: Innovative treatment strategies under investigation for recurrent high-grade meningiomas include targeted therapies, immunotherapy, and radionuclide-based approaches. Inhibition of angiogenesis, histone deacetylases, FAK, mTOR, and CDK4/6 pathways has shown early signs of activity in small clinical trials of patients with recurrent meningiomas. Immunotherapy, such as immune checkpoint inhibition (ICI), has also demonstrated prolonged disease control in a subset of patients. Larger randomized studies are needed for further investigation of the efficacy and safety of these newer therapies in patients with high-grade and recurrent meningioma.Summary: Emerging molecularly driven treatment strategies show promise for the treatment of patients with high-grade meningiomas. Larger trials that incorporate molecular testing are warranted to fully evaluate their therapeutic potential.","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WCO.0000000000001430","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Patients with grade 2 and 3 meningioma have high recurrence rates and limited treatment options after failure of radiation and surgery. Recent advances in molecular profiling of these tumors have enabled the investigation of novel targeted therapeutic approaches.

Recent findings: Innovative treatment strategies under investigation for recurrent high-grade meningiomas include targeted therapies, immunotherapy, and radionuclide-based approaches. Inhibition of angiogenesis, histone deacetylases, FAK, mTOR, and CDK4/6 pathways has shown early signs of activity in small clinical trials of patients with recurrent meningiomas. Immunotherapy, such as immune checkpoint inhibition (ICI), has also demonstrated prolonged disease control in a subset of patients. Larger randomized studies are needed for further investigation of the efficacy and safety of these newer therapies in patients with high-grade and recurrent meningioma.

Summary: Emerging molecularly driven treatment strategies show promise for the treatment of patients with high-grade meningiomas. Larger trials that incorporate molecular testing are warranted to fully evaluate their therapeutic potential.

查看原文本刊更多论文

新兴的脑膜瘤靶向治疗。

回顾目的：2级和3级脑膜瘤患者在放疗和手术失败后复发率高，治疗选择有限。这些肿瘤分子谱的最新进展使得新的靶向治疗方法的研究成为可能。最新发现：正在研究的复发性高级别脑膜瘤的创新治疗策略包括靶向治疗、免疫治疗和基于放射性核素的方法。在复发性脑膜瘤患者的小型临床试验中，血管生成、组蛋白去乙酰化酶、FAK、mTOR和CDK4/6途径的抑制已显示出早期活性迹象。免疫疗法，如免疫检查点抑制（ICI），也证明了在一部分患者中延长了疾病控制。需要更大规模的随机研究来进一步研究这些新疗法对高级别和复发性脑膜瘤患者的疗效和安全性。总结：新兴的分子驱动治疗策略显示出治疗高级别脑膜瘤患者的希望。纳入分子检测的更大规模的试验是有必要的，以充分评估其治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Neurology 医学-临床神经学

CiteScore

8.60

自引率

0.00%

发文量

174

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Neurology is a highly regarded journal offering insightful editorials and on-the-mark invited reviews; covering key subjects such as cerebrovascular disease, developmental disorders, neuroimaging and demyelinating diseases. Published bimonthly, each issue of Current Opinion in Neurology introduces world renowned guest editors and internationally recognized academics within the neurology field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.